Skip to main content
SpringerLink
Log in

New indications for 6-azauridine treatment in man. A review

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The antimetabolite 6-azauridine and its triacetate derivative exemplify the problems of developing new drugs for use in man. They showed promising cytostatic properties and very low toxicity in animal experiments. However, they had little effect on human leukemia, although the low toxicity was confirmed in man. They were active against mycosis fungoides and psoriasis. Doses of 6-azauridine well tolerated in all other diseases caused serious early toxic reactions in cases of rheumatoid arthritis. There were other discrepancies between the results of studies in man and animals. — Thein vitro activity against vaccinia virus was confirmed in a controlled clinical trial in smallpox. Promising results were also obtained in patients with ocular herpes simplex. The significance of these results is discussed in terms of the assessment of new drug treatments in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bauer, D.J., Sadler, P.W.: New antiviral chemotherapeutic agent active against small-pox infection. Lancet1960 I, 1110–1111.

    Google Scholar 

  2. —— Vincent, L.S., Kempe, C.H., Downie, A.W.: Prophylactic treatment of small-pox contacts with N-methylisatin-β-thiosemicarbazone (compound 33 I 57, Marboran). Lancet1963 II, 494–496.

    Google Scholar 

  3. Beránek, J., Pitha, J.: Nucleic acid components and their analogues XLVI. Some derivates of 6-azacytidine and 6-azauridine. Coll. Czech. Chem. Comm.29, 625–633 (1964).

    Google Scholar 

  4. —— Šorm, F.: Nucleic acid components and their analogues XXIX. The synthesis of 6-azacytidine-5′-phosphate and 5′-diphosphate. Coll. Czech. Chem. Comm.28, 469–480 (1963).

    Google Scholar 

  5. Breeden, C.J., Hall, T.C., Tyler, H.R.: Herpes simplex encephalitis treated with systemic 5-iodo-2′-deoxyuridine. Ann. intern. Med.65, 1050–1056 (1966).

    Google Scholar 

  6. Burch, P.R.J., Rowell, N.R.: Psoriasis: Aetiological aspects. Acta derm.-venerol. (Stockh.)45, 366–373 (1966).

    Google Scholar 

  7. Calabresi, P.: Current status of clinical investigations with 6-azauridine, 5-iodo-2′-deoxyuridine and related derivates. Cancer Res.23, 1260–1261 (1963).

    Google Scholar 

  8. Calabresi, P., Turner, R., Lefkowitz E.R.: Beneficial effects of azauridine in psoriasis and mycosis fungoides. Proc. Amer. Ass. Cancer Res.5, 10 (1964).

    Google Scholar 

  9. —— —— Beneficial effects of triacetyl-azauridine in psoriasis and mycosis fungoides. Ann. intern. Med.64, 352–371 (1966).

    Google Scholar 

  10. Cotton, D.K.W., Mier, P.D.: An hypothesis on the selectivity of psoriasis. Brit. J. Derm.76, 519–520 (1964).

    Google Scholar 

  11. Elis, J., Janků, I.: Zur Pharmakologie des Azauracilribosids. Naunyn-Schmiedebergs Arch. Pharmak.245, 128–129 (1963).

    Google Scholar 

  12. —— Rašková, H.: Controlled clinical trial with new cytostatic preparations produced in Czechoslovakia. Rev. Czech. Med.12, 9–19 (1966).

    Google Scholar 

  13. —— Slavík, M., Rašková, H.: Side-effects of 6-azauridine triacetate in rheumatoid arthritis. Clin. Pharm. Ther.11, 404–407 (1970).

    Google Scholar 

  14. Elves, M.W., Buttoo, A.S., Israelstam, C.G., Wilkinson, J.F.: Chromosomal changes caused by 6-azauridine during treatment of acute myeloblastic leukemia. Brit. med. J.1963 I, 153–159.

    Google Scholar 

  15. Falke, M., Rada, B.: 6-Azauridine as an inhibitor of the synthesis of herpes virus hominis. Acta Virol.14, 115–123 (1970).

    Google Scholar 

  16. Falkson, G.: Halogenated pyrimidine and herpes simplex. Med. Proc.9, 332–333 (1963).

    Google Scholar 

  17. Fallon, H.J., Frei, E., Block, L., Seegemiller, J.E.: The uricosuria and orotic aciduria induced by 6-azauridine. J. clin. Invest.40, 1906–1913 (1961).

    Google Scholar 

  18. Fischer, D.S., Cassidy, E.P., Welch, A.D.: Immunosupression by pyrimidine nucleoside analogs. Biochem. Pharmacol.15, 1013–1022 (1966).

    Google Scholar 

  19. Fosdick, W.M.: Cytotoxic therapy in rheumatoid arthritis. Med. Clin. N. Amer.52, 747–757 (1968).

    Google Scholar 

  20. Frohberg, H.: The evaluation of mutagenicity tests within the scope of toxicological trial. Arch. Toxikol.28, 135–148 (1971).

    Google Scholar 

  21. Galegov, G.A., Kukhar, E.E., Bikbulatov, R.M.: Treatment of keratitis in rabbits due to herpes simplex virus with 6-azauridine (Russian). Voprosy Virologii15, 351–354 (1970).

    Google Scholar 

  22. Grimová, J.: Adjuvant induced disease in rats. Ph.D. Thesis. Research Institute of Pharmacy and Biochemistry, p. 142–155, Prague, 1969.

    Google Scholar 

  23. Gutová, M., Elis, J., Rašková, H.: Teratogenic effect of 6-azauridine in rats. Teratology4, 287–294 (1971).

    Google Scholar 

  24. Habermann, V., Šorm, F.: Mechanism of the cancerostatic action of 6-azauracil and its riboside. Coll. Czech. Chem. Comm.23, 2201–2206, (1958).

    Google Scholar 

  25. Handbook for small-pox eradication. Programmes in the endemic areas. World Health Organization, June, 1967.

  26. Handschumacher, R.E.: Metabolites of 6-azauracil formed by Streptococcus faecalis. Fed. Proc.16, 191 (1957).

    Google Scholar 

  27. —— Studies of bacterial resistance to 6-azauracil and its riboside. Biochim. biophys. Acta.23, 428–430 (1957).

    Google Scholar 

  28. —— Pasternak, C.A.: Inhibition of orotidylic acid decarboxylase, a primary site of carcinostatic by 6-azauracil. Biochim. biophys. Acta30, 451–452 (1958).

    Google Scholar 

  29. —— Orotidylic acid decarboxylase with azauridine 5′-phosphate. J. biol. Chem.235, 2917–2919 (1960).

    Google Scholar 

  30. —— Calabresi, P., Welch, A.D., Bono, V., Fallon, H.J., Frei: Summary of current information of 6-azauridine. Cancer Chemother. Rep.21, 1–18 (1962).

    Google Scholar 

  31. Havelka, S., Pěgřimová, E., Trnavsky, K., Slavík, M., Elis, J.: 6-Azauridin-Triacetat in der Therapie der chronischen Polyarthritis. Zeitschr. f. Rheumaforsch.28, 29–35 (1969).

    Google Scholar 

  32. Heidelberger, C.: Cancer Chemotherapy with Purine and Pyrimidine Analogues. Ann. Res. Pharm.7, 101–124 (1967).

    Google Scholar 

  33. Jaffe, J.J., Handschumacher, R.E., Welch, A.D.: Studies on the carcinostatic activity in mice of 6-azauracil riboside (azauridine) in comparison with that of 6-azauracil. Yale J. Biol. Med.30, 168–175 (1957).

    Google Scholar 

  34. Janků, I.: The possibilities of detection of adverse reactions of drugs from animal experiment. Thesis, Charles University, Prague, December, 1967.

    Google Scholar 

  35. Jasiňska, S., Link, F., Blaškovič, D., Rada, B.: Studies on the effect of antiviral substances on experimental virus infections. III. The effects of 6-azauracil riboside urethane on vaccinia virus infection in mice. Acta Virol.6, 17–23 (1962).

    Google Scholar 

  36. Jiřička, Z., Smetana, K., Janků, I., Elis, J., Novotný, J.: Studies on 6-azauridine and 6-azacytidine. I. Toxicity studies of 6-azauridine and 6-azacytidine in mice. Biochem. Pharmacol.14, 1517–1523 (1965).

    Google Scholar 

  37. Mísařová, Z., Elis, J.: The treatment of children leukemia with 6-azauracilriboside and its triacetate (In Czech). Čs. Pediatrie19, 161–165 (1964).

    Google Scholar 

  38. Nouza, K.: Screening of immunosuppressive drugs in the allotransplantation reaction between mice differing at the 83-H locus. Folia Biologica12, 266–277 (1966).

    Google Scholar 

  39. Scientific Information Service, United Pharmaceutical Works (SPOFA) Prague, 1960–1962.

  40. Pasternak, C.A., Handschumacher, R.E.: The biochemical activity of 6-azauridine: Interference with pyrimidine metabolism in transplantable mouse tumors. J. biol. Chem.234, 2992–2997 (1959).

    Google Scholar 

  41. Plevová, J.: Pharmacokinetics of 6-azauridine triacetate (In Czech), Ph.D. Thesis, Charles University, Prague, 1969.

    Google Scholar 

  42. Rada, B., Blaškovič, D.: Inhibitions of vaccinia virus multiplication in vitro by 6-azauracilriboside. Acta Virol.5, 308–316, (1961).

    Google Scholar 

  43. —— —— Some characteristics of the effects of 6-azauridine on vaccinia virus multiplication, in comparison with those of 5′-iododeoxyuridine. Acta Virol.10, 1–9 (1966).

    Google Scholar 

  44. —— —— Šorm, F., Škoda, J.: The inhibitory effect of 6-azauracil riboside on the multiplication of vaccinia virus. Experientia16, 487–488 (1960).

    Google Scholar 

  45. —— Gegušová, V.: Increase of uridine kinase activity after infection of cells with vaccinia and Rous sarcoma viruses. Biochem. biophys. Res. Commun.15, 324–328 (1964).

    Google Scholar 

  46. Rašková, H., Elis, J.: Some new indications for 6-azauridine and 6-azauridine triacetate. Soc. Pharmacol. Hung. V. Conf. Hung. pro Therap. et Investigatione in Pharmacologia, p. 561–565. Budapest 1968, ed. 1971.

  47. Rosenbergová, M., Rada, B.: Synthesis of cellular nucleic acids during inhibition of vaccinia virus multiplication by 6-azauracil riboside. Acta Virol.6, 258–265 (1962).

    Google Scholar 

  48. Schindler, R., Welch, A.D.: Studies of inhibitory activity of 6-azauracil riboside and related compounds on Sarcoma 180 in tissue culture. Proc. Amer. Ass. Cancer Res.2, 247 (1957).

    Google Scholar 

  49. Slavík, M., Elis, J., Rašková, H., Gutová, M., Duchková, M., Kubíková, M., Seyček, V.: Therapeutic effects of 6-azauridine triacetate in psoriasis. Pharm. Clin.2, 120–125 (1970).

    Google Scholar 

  50. Škoda, J., Hess, W.F., Šorm, F.: 1. Production of 6-azauracilriboside by Escherichia coli growing in the presence of 6-azauracil. Coll. Czech. Chem. Comm.22, 1330–1333 (1957).

    Google Scholar 

  51. —— —— —— 2. The biosynthesis of 6-azauracilriboside by Escherichia coli growing in the presence of 6-azauracil. Experientia13, 150–151 (1957).

    Google Scholar 

  52. Šmejkal, F., Šorm, F.: The effect of 6-azauracil riboside against vaccinia virus in rabbits. Acta Virol.6, 282 (1962).

    Google Scholar 

  53. Šorm, F., Keilová, H.: The anti-tumour activity of 6-azauracil riboside. Experientia14, 215 (1958).

    Google Scholar 

  54. Šterzl, J.: Effect of some metabolic inhibitors on antibody formation. Nature189, 1022–1023 (1961).

    Google Scholar 

  55. Vogler, W.R., Olansky, S.: A double-blind study of azaribine in the treatment of psoriasis. Ann. int. Med.73, 951–956 (1970).

    Google Scholar 

  56. Záruba, F., Kůta, A., Elis, J.: The treatment of mycosis fungoides with 6-azauracilriboside. Lancet1963, No 7272, p. 275

Download references

Author information

Authors and Affiliations

  1. Institute of Pharmacology, Czechoslovak Academy of Sciences, Prague, Czechoslovakia

    J. Elis & H. Rašková

Authors
  1. J. Elis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Rašková
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elis, J., Rašková, H. New indications for 6-azauridine treatment in man. A review. Eur J Clin Pharmacol 4, 77–81 (1972). https://doi.org/10.1007/BF00562501

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00562501

Key words

Search

Navigation